AZITHROMYCIN MBI 500 MGVIAL

Страна: Израел

Език: английски

Източник: Ministry of Health

Активна съставка:

AZITHROMYCIN AS DIHYDRATE

Предлага се от:

MBI PHARMA LTD., ISRAEL

АТС код:

J01FA10

Лекарствена форма:

POWDER FOR SOLUTION FOR INFUSION

Композиция:

AZITHROMYCIN AS DIHYDRATE 500 MG

Начин на приложение:

I.V

Вид предписание :

Required

Произведено от:

ALTAN PHARMACEUTICALS, S.A., SPAIN

Терапевтична област:

AZITHROMYCIN

Терапевтични показания:

Treatment of infections caused by susceptible strains of the designated microorganisms in the following conditions: community-acquired pneumonia and pelvic inflammatory disease.

Дата Оторизация:

2023-06-30

Листовка

MBI PHARMA
המרפ ייא.יב.םא
62 HA’SHAHAF STREET ףחשה 'חר
62
TEL MOND
דנומ לת
TEL: [phone] :'לט
7719003
-
09
FAX: [phone] :סקפ
7719990
-
09
ה/אפור
ה/דבכנ
,
ה/דבכנ ת/חקור
,
תרבח
פ ייא.יב.םא
א
המר
קוויש תליחת לע ךעידוהל החמש
ו
שדחה רישכת לש
ZITHROMYCIN MBI 500MG/VIAL
A
תרוצ
:ןונימ
POWDER FOR SOLUTION FOR INFUSION
ליעפ ביכרמ
:
500 mg
AZITHROMYCIN ( AS DIHYDRATE )
ה
מ רישכת
דעוי
:היוותהל
Treatment of infections caused by susceptible strains of the
designated microorganisms
in the following conditions: community-acquired pneumonia and pelvic
inflammatory
disease.
לעה
ו
ן
אפורל
םסרופמ
רגאמב
ינו ,תואירבה דרשמ רתאבש תופורתה
לבקל ןת
ו
הינפ ידי לע ספדומ
םושירה לעבל
,
תרבח
המרפ ייא.יב.םא
,
ד.ת
5061
.לט ןופלטב וא ,המידק ,
7719903
-
09
.
,הכרבב
רוד רנבא
הנוממ חקור

Данни за продукта

AZITHROMYCIN MBI 500 MG/VIAL
1. QUALITATIVE AND QUANTITATIVE COMPOSITION
One vial contains 500 mg azithromycin base (equivalent to 524
azithromycin dihydrate) and gives a concentrate of
100 mg/ml azithromycin base after reconstitution.
Excipients with known effect:
101.5 mg (4.4 mmol) of sodium per vial.
For the full list of excipients, see section _Description _(11) in
this leaflet.
Pharmaceutical form:
Powder for solution for infusion.
2.
INDICATIONS AND USAGE
Treatment of infections caused by susceptible strains of the
designated microorganisms in the following conditions:
community-acquired pneumonia (CAP) and pelvic inflammatory disease
(PID).
3.
DOSAGE AND ADMINISTRATION
For the treatment of adult patients with CAP due to the indicated
organisms, the recommended dose of intravenous
azithromycin is 500 mg as a single daily dose by the IV route for at
least two days. Intravenous therapy should be followed
by oral azithromycin at a single daily dose of 500 mg to complete a 7
to 10 day course of therapy. The timing of the
conversion to oral therapy should be done at the discretion of the
physician and in accordance with clinical response.
For the treatment of adult patients with PID due to the indicated
organisms, the recommended dose of intravenous
azithromycin is 500 mg as a single dose by the IV route for one or two
days. Intravenous therapy should be followed by
azithromycin by the oral route at a single daily dose of 250 mg to
complete a 7-day course of therapy. The timing of the
conversion to oral therapy should be done at the discretion of the
physician and in accordance with clinical response. If
anaerobic microorganisms are suspected of contributing to the
infection, an antimicrobial anaerobic agent may be
administered in combination with azithromycin.
After reconstitution and dilution, the recommended route of
administration for intravenous azithromycin is by IV infusion
only.
DO NOT ADMINISTER AS AN INTRAVENOUS BOLUS OR AN INTRAMUSCULAR
INJECTION.
The infusate concentration and rate of infusion for a